NCT00290251 2024-07-15
Treatment of Uterine Fibroids With the Selective Progesterone Receptor Modulator CDB-2914
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
Clinical Trials
24 trialsNCT01441635 2021-07-13
Safety and Efficacy of Elagolix in Pre-Menopausal Women With Heavy Uterine Bleeding and Uterine Fibroids
AbbVie
Phase 2 Completed
NCT01817530 2020-07-21
Safety and Efficacy in Premenopausal Women With Heavy Menstrual Bleeding (HMB) Associated With Uterine Fibroids (UF)
AbbVie
Phase 2 Completed
NCT02166411 2020-03-13
Laparoscopic Myomectomy Using Barbed or Conventional Sutures
Cairo University
Phase 2 Completed
NCT00044876 2019-12-17
Treatment of Uterine Fibroids With CDB-2914, an Experimental Selective Progesterone Receptor Antagonist
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT02270255 2019-08-14
Superior Hypogastric Nerve Block for Pain Control Post-uterine Fibroid Embolization
McGill University Health Centre/Research Institute of the McGill University Health Centre
Phase 2 Completed
NCT02323646 2019-06-25
Safety and Efficacy of Telapristone Acetate (Proellex®) Administered Vaginally for the Treatment of Uterine Fibroids
Repros Therapeutics Inc.
Phase 2 Completed
NCT00839722 2019-06-20
EFU
Assistance Publique - Hôpitaux de Paris
Phase 2 Completed
NCT02301897 2019-06-19
A Multi-Center, Parallel Design, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of 6 and 12 mg Proellex® (Telapristone Acetate) Administered Orally in the Treatment of Premenopausal Women With Confirmed Symptomatic Uterine Fibroids
Repros Therapeutics Inc.
Phase 2 Completed
NCT00958334 2019-06-18
Extension Study of Proellex in Women Who Have Previously Completed Study ZPU 003
Repros Therapeutics Inc.
Phase 2 Completed
NCT02131662 2017-12-08
ASTEROID 1
Bayer
Phase 2 Completed
NCT00332033 2017-07-02
Development of a Non-Invasive Treatment for Uterine Leiomyoma (Fibroids)
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT02465814 2016-11-22
ASTEROID 2
Bayer
Phase 2 Completed
NCT01451424 2014-08-29
Evaluation of Safety, Pharmacokinetics, and Efficacy of Proellex Administered Vaginally in Women With Uterine Fibroids
Repros Therapeutics Inc.
Phase 2 Completed
NCT00882258 2014-07-08
Study of Proellex in Pre-menopausal Women With Symptomatic Uterine Fibroids
Repros Therapeutics Inc.
Phase 2 Completed
NCT01631903 2014-04-16
Extension of Study ZPV-200
Repros Therapeutics Inc.
Phase 2 Completed
NCT01739621 2014-04-16
Safety, Pharmacokinetics and Efficacy of Proellex® (Telapristone Acetate) Administered Vaginally in the Treatment of Premenopausal Women With Uterine Fibroids Who Have Completed ZPV-200
Repros Therapeutics Inc.
Phase 2 Completed
NCT01452659 2013-01-21
Efficacy and Safety of TAK-385 in the Treatment of Uterine Fibroids
Takeda
Phase 2 Completed
NCT00881140 2012-12-19
Efficacy Study of Vaginal Mifepristone to Treat Uterine Fibroids
BioPro Medical Ltd
Phase 2 Completed
NCT00776074 2010-06-22
A Pharmacodynamic Study of Leuprorelin Gelatin-Free Formulation in Female Subjects With Uterine Fibroids.
Takeda
Phase 2 Completed
NCT00156182 2009-03-04
A Long-Term Safety Study of Asoprisnil in the Treatment of Uterine Fibroids.
Abbott
Phase 2 Completed
NCT00150644 2008-05-29
A Study to Evaluate the Effects of Asoprisnil(J867) in Women With Uterine Fibroids Who Are Scheduled for a Hysterectomy
Abbott
Phase 2 Completed
NCT00160459 2008-05-29
A Study to Evaluate the Safety and Effectiveness of Asoprisnil in the Treatment of Uterine Fibroids
Abbott
Phase 2 Completed
NCT00087841 2008-01-17
Self-Hypnotic Relaxation Therapy During Invasive Procedures
National Center for Complementary and Integrative Health (NCCIH)
Phase 2 Completed